Investors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by ...

Learn more Prominent biotech Biogen (NASDAQ: BIIB) loomed large on the stock market on Wednesday. It published its latest set ...

Biogen’s growth was expected to stay flat through the 2030s. A key acquisition and busy late-stage pipeline have relieved the ...

On Apellis, "we have the proposed Apellis acquisition" and "we do expect the acquisition to be accretive in 2027" (CEO Viehbacher). "Total revenue was $2.5 billion" and "non-GAAP diluted EPS of $3.57" ...

Biogen (BIIB) stock is in focus as the company beats forecasts with its Q1 2026 financials and trims its full-year earnings ...

April 29 (Reuters) - Biogen cut its full-year profit forecast on Wednesday as it booked acquisition-related charges, although ...

Key dosing differences between Eli Lilly’s Kisunla and Biogen’s Leqembi are about to come to a head in the Alzheimer's market ...

Biogen lowered its earnings guidance and projected weaker revenue for 2026, tempering the impact of a first-quarter rise in both sales and profit.

Leqembi, which was approved in 2023 to treat the mind-robbing disease, generated $168 million in sales, up 74 percent from ...

Shares of Biogen Inc. BIIB shed 2.62% to $189.28 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 1.02% to 7,209.01 and the ...

Biogen has entered into an agreement with TJ Biopharma (TJ Bio) to acquire exclusive rights to felzartamab in the Greater ...

Biogen (NASDAQ:BIIB | BIIB Price Prediction) picked up a strong endorsement from Wall Street on Wednesday, as UBS analyst ...